|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with morphologic and molecular features akin to invasive ductal carcinoma of the breast, including HER2 gene amplification, mutations of TP53, PIK3CA, and HRAS and loss or mutation of PTEN.
|
29076877 |
2018 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
KRAS2 gene mutations are found in 75-90% of infiltrating pancreatic ductal adenocarcinomas but can also be present with other nonneoplastic pancreatic diseases.
|
18075308 |
2008 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Pancreatic ductal adenocarcinomas exhibit the highest incidence of activating KRAS (Ki-Ras) mutations observed in any human cancer.
|
16598499 |
2006 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
|
16774944 |
2006 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The combined HR was 1.35 (95% CI: 1.16-1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26-2.02) and in studies using PCR (HR 1.40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34).
|
15597105 |
2005 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Microsatellite instability in sporadic and inherited colon adenocarcinomas from Greek patients: correlation with several clinicopathological characteristics.
|
16268414 |
2005 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inactivation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas.
|
14511407 |
2004 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
KRAS2 mutations were found in four out of 19 (21%) Barrett's adenocarcinomas examined and in three cases of HGIN (11%).
|
14724583 |
2004 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in k-ras-2 were seen in 25% and 19% of RC and NRC tumors, respectively, most frequently in adenocarcinomas.
|
12527710 |
2003 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status.
|
12696070 |
2003 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased copy number of the ERBB2 (1 of 22), GATA4 (1 of 22), KRAS (2 of 22), C-MYC (1 of 22), CCNE1 (2 of 22), and CCND1 (2 of 22) genes was also observed in one or more Barrett's adenocarcinomas with HGD.
|
14581353 |
2003 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we report that loss of heterozygosity (LOH) of chromosome 12p was detected in approximately 50% of human lung adenocarcinomas and large cell carcinomas, and Kras2 mutations were detected at codon 12 in approximately 40% of adenocarcinomas and large cell carcinomas.
|
12606951 |
2003 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the other tumors, more complex aberrations were visualized, including two inversions in 12q with a common breakpoint between MDM2 and D12S332 in a pleomorphic adenoma, amplification of MDM2 and CDK4 in ring chromosomes from a malignant fibrous histiocytoma, and amplification of KRAS2 together with other unbalanced rearrangements in two pancreatic adenocarcinomas.
|
10862042 |
2000 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Meanwhile, 11 (58 per cent) serrated adenomas and six (60 per cent) adenocarcinomas in/with serrated adenomas had Ki-ras gene mutations, as also did 9 of 23 (39 per cent) hyperplastic nodules, 3 of 4 (75 per cent) hyperplastic polyps, and 12 of 29 (41 per cent) tubular adenomas.
|
9924427 |
1998 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Amplification of KRAS2 was detected in two adenocarcinomas by Southern blot analysis.
|
9460997 |
1998 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Ki-ras gene mutation was detected in 12 of 20 (60%) mucin-producing adenocarcinomas.
|
9234384 |
1997 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Adenocarcinomas from the left side of the colorectum showed a significant association between C-KI-RAS activation and tumour progression, including the presence of distant organ metastasis at the time of surgery (P = 0.0039), and during patient follow-up (P = 0.00027), whereas those from the right of the colorectum did not (P = 0.4 and P = 0.5, respectively).
|
8814697 |
1996 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Topographic genotyping with subsequent polymerase chain reaction (PCR) and sequence analysis of K-ras-2 showed mutations in significantly fewer cases of PC (9%, 2 of 22 cases) than in AdC (36%, 35 of 97 cases) or SqC (0%, 0 of 42 cases) (P < .001).
|
8853037 |
1996 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight of 22 prostate adenocarcinomas (three of nine (33.3%) from the ventral lobe and five of 13 (38.5%) from the dorsolateral lobe, including three transplantable tumors) and one of 11 seminal vesicle adenocarcinomas (9.1%) demonstrated point mutations in the Ki-ras gene.
|
7766307 |
1995 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These findings provide the first evidence for amplification of the Ki-ras gene in human esophageal cancer, which is restricted to adenocarcinomas.
|
8519418 |
1995 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seventy-seven pancreatic adenocarcinomas (60 Spanish and 17 Italian) were tested for Ki-ras gene mutations by analysis of polymerase chain reaction amplified sequences.
|
8157353 |
1994 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HPV DNA type 16 or 18 in cervical adenocarcinomas was detected in 35% of cases by PCR and in 29% by Southern blotting, and, in contrast to the p53 mutations, the majority of cases with the HPV DNA were at a relatively early clinical stage with low-grade histological atypia. c-Ki-ras gene mutation was detected in only 4% of cervical adenocarcinomas.
|
7960232 |
1994 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung.
|
7910096 |
1994 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight pancreatic adenocarcinomas in the range 1.2-3 cm were analyzed for c-K-ras mutation at codon 12 by amplifying the c-K-ras gene around codon 12 out of paraffin-embedded tissue sections using the polymerase chain reaction. c-K-ras mutations were detected by allele-specific oligonucleotide hybridization.
|
8190717 |
1994 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the 16 samples adequate for PCR/RFLP analysis, a c-Ki-ras gene mutation was detected in 11 (92%) of 12 adenocarcinomas.
|
7902444 |
1993 |